- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03236272
Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)
March 23, 2020 updated by: Mingdong Hu
The aim of the investigators 'study is to investigate the relationship between the biomarkers (e.g. protein markers, genetic polymorphisms and epigenetic markers) and the onset of ARDS.
In this study, the participants were divided into case group (with ARDS) and control group (without ARDS), based on a nested case-control study method.
During the diagnosis and treatment, the clinical data of subjects are collected at the given time point.
And the clinical data are extracted from plasma, blood and bronchoalveolar lavage fluid of participants.
These data will be analyzed based on statistical methods.
In the end ,the investigators can build a multi index early warning model based on the biomarkers,which is meaningful for the early diagnosis of the patient with high-risk for ARDS and provide evidence for the early treatment.
Study Overview
Status
Unknown
Conditions
Detailed Description
The investigators studied patients at high risk of acute respiratory distress syndrome (ARDS) and ARDS patients.
The patients with ARDS were the case group, and the patients without ARDS were the control group .Sample size estimate :set alpha =0.05,1- beta =0.8, estimated cases exposure rate was 50%, the control group estimated exposure rate was 35%, according to a case-control study of sample size estimation formula for sample size calculation, and considering the loss rate is 10%, the sample size for each group of 188 cases, two groups of 376 cases.
The plasma, blood and bronchoalveolar lavage fluid will be collected during the diagnosis and treatment,to study biomarkers related to the onset of ARDS, such as protein markers,genetic polymorphisms and epigenetic markers.The observation data of two groups will be compared .The clinical data are collected at the given time point.
The stepwise regression (forward-conditional) will be used for establishing a multivariate unconditional logistic regression model that will contribute to screened the main risk factor and protective factors that affect the ARDS.
And these factor will help to established the early warning model and the risk function of ARDS in high-risk patients, which will contribute to predict the risk of ARDS in high-risk patients.All information about the subjects is strictly confidential, and the results of the study may be reported at medical conferences and published in scientific journals, but any individual who can identify subjects will not be able to use.
Study Type
Observational
Enrollment (Anticipated)
376
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hu Mingdong, MD
- Phone Number: 13500362524
- Email: huhanshandd@163.com
Study Contact Backup
- Name: Wang dan
- Phone Number: 18581290211
- Email: wada211@163.com
Study Locations
-
-
-
Chongqing, China
- Recruiting
- Center of Respiratory and Critical Care Medicine,Department Of Gerontology and Secret Service Medicine, Xinqiao Hospital, Third Military Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The subjects were selected from the Department of respiration, Xinqiao Hospital of Chongqing city
Description
Inclusion Criteria:
High-risk cases ARDS inclusion criteria:
- Acute onset (within 1 weeks)
- Pneumonia,Aspiration,Sepsis,Acute pancreatitis,Shock,High-risk trauma and other unexpected severe diseases.
- Pao2/Fio2>300mmhg
- 18 to 80 years old
- The subjects agreed to sign the informed consent
ARDS Inclusion criteria:
- Acute onset (within 1 weeks)
- Pneumonia,Aspiration,Sepsis,Acute pancreatitis,Shock,High-risk trauma and other unexpected severe diseases.
- Pao2/Fio2<300mmhg
- 18 to 80 years old
- The subjects agreed to sign the informed consent
Exclusion Criteria:
- patients who developed ARDS before initial evaluation or blood collection
- patients who were rehospitalized
- the hospital stay was shorter than 7 days, and it was unfeasible to determine the clinical outcome
- patients who died within 6h of admission
- patients had a history of chronic interstitial lung disease
- patients with an age of less than 18 years old
- Patients were immunodeficiency (eg, eukaemia) or treated with cytotoxic drugs
- patients who were pregnant
- patients who were refused to join.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
case group
patients with ARDS
|
control group
patients Without ARDS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change of protein biomarkers expression
Time Frame: Day 0,Day 1,Day 2,Day 3,Day 4,Day 7 and Day 14 post-enrollment.
|
The protein biomarkers include surfactant protein(SP-D),Clara Cell Protein 16(CC-16),Angiopoietin-2(Ang-2),von Willebrand factor(vWF),Lipopolysaccharide-Binding Protein(LBP) and plasminogen activator inhibitor-1(PAI-1).The subjects will be observed for the content and expression changes of the items mentioned above at day0,1,2,3,4,7.
Among participants, for case group patients ,the observation time point,day14 will be added.
|
Day 0,Day 1,Day 2,Day 3,Day 4,Day 7 and Day 14 post-enrollment.
|
the change of microRNA-126(miR-126) expression
Time Frame: Day 0,Day 1,Day 2,Day 3,Day 4,Day 7 and Day 14 post-enrollment.
|
The subjects will be observed for the content and expression changes of the miR-126 at day0,1,2,3,4,7.
Among participants, for case group patients ,the observation time point,day14 will be added.
|
Day 0,Day 1,Day 2,Day 3,Day 4,Day 7 and Day 14 post-enrollment.
|
the change of microRNA-146a(miR-146a) expression
Time Frame: Day 0,Day 1,Day 2,Day 3,Day 4,Day 7 and Day 14 post-enrollment.
|
The subjects will be observed for the content and expression changes of the miR-146a at day0,1,2,3,4,7.
Among participants, for case group patients ,the observation time point,day14 will be added.
|
Day 0,Day 1,Day 2,Day 3,Day 4,Day 7 and Day 14 post-enrollment.
|
Detection of methylation of occludin (OCLN) gene
Time Frame: Day 0,Day 1,Day 2,Day 3,Day 4,Day 7 and Day 14 post-enrollment.
|
Detecting the OCLN gene methylation is based on microarray methylation pattern analysis.The subjects will be detected OCLN gene methylation at day0,1,2,3,4,7.
Among participants, for case group patients ,the observation time point day14 will be added.
|
Day 0,Day 1,Day 2,Day 3,Day 4,Day 7 and Day 14 post-enrollment.
|
Analysis of gene polymorphism
Time Frame: Day 0
|
Detecting the genetic polymorphisms,it include mannose binding lectin-2 gene (The Single Nucleotide Polymorphism database (dbSNP) identification number (ID): rs1800450) and lipopolysaccharide-binding peptide (LBP) gene(The Single Nucleotide Polymorphism database (dbSNP) ID: rs2232618)
|
Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 15, 2017
Primary Completion (ANTICIPATED)
December 31, 2020
Study Completion (ANTICIPATED)
December 31, 2020
Study Registration Dates
First Submitted
July 24, 2017
First Submitted That Met QC Criteria
July 27, 2017
First Posted (ACTUAL)
August 1, 2017
Study Record Updates
Last Update Posted (ACTUAL)
March 25, 2020
Last Update Submitted That Met QC Criteria
March 23, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMMUHMD76
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome, Adult
-
Wolfson Medical CenterUnknown
-
Centre Hospitalier Universitaire de NiceCompletedRespiratory Distress Syndrome,AdultFrance
-
Abbott NutritionTerminatedAcute Lung Injury | Respiratory Distress Syndrome,AdultRussian Federation
-
GlaxoSmithKlineTerminatedLung Injury, Acute and Respiratory Distress Syndrome, AdultUnited Kingdom
-
Amazon UniversitySanta Casa de Misericórdia do ParáCompletedSepsis | HELLP Syndrome | Postpartum Period | Respiratory Distress Syndrome,Adult
-
Michael A. MatthayThe University of Texas Health Science Center, Houston; United States Department... and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Faron Pharmaceuticals LtdSeventh Framework ProgrammeTerminatedRespiratory Distress Syndrome, AdultSpain, United Kingdom, France, Italy, Finland, Czechia, Belgium, Germany
-
Karolinska University HospitalKarolinska InstitutetUnknownAcute Respiratory Distress Syndrome, AdultSweden
-
Michael A. MatthayMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Chang Gung Memorial HospitalUnknownRespiratory Distress Syndrome, AdultTaiwan